Femasys Inc (FEMY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$2.98-2.61%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · FEMY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on expanding commercial adoption of FemaSeed fertility portfolio and advancing FemBloc clinical and regulatory programs toward U.S. approval.
Stated as a priority in 2 of last 2 quarters. Sales grew modestly from $750,532 in 2025 to $756,716 in first half 2026, with a 24.5% increase in 2026-Q1 driven by FemBloc and a slight decline in 2026-Q2 due to lower FemVue sales. Management has advanced commercialization of FemaSeed and progressed FemBloc clinical enrollment, delivering on stated growth initiatives with mixed revenue trajectory.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Completed $30 million private placement to enable execution of U.S. commercial strategy for FemaSeed and advancement of FemBloc clinical program.”
“Advanced initial commercial adoption of FemaSeed Complete and initiated patient enrollment in FemBloc pivotal clinical trial.”
Maintain adequate liquidity to support ongoing operations through the third quarter of 2026, including recent financing efforts.
Stated as a priority in 3 of last 3 quarters. Cash and equivalents declined from approximately $5.4 million in 2026-Q1 to $1.4 million in 2026-Q2, but management completed a $30 million private placement in 2026-Q2 to strengthen liquidity. Management consistently affirmed sufficient cash to fund operations into Q3 2026, reflecting mixed but supported liquidity status.
“Completed $30 million private placement; believe cash resources sufficient to fund operations into Q3 2026.”
“We believe our current cash resources are sufficient to fund operations into the third quarter of 2026.”
“Company expects cash and equivalents sufficient to fund ongoing operations into September 2026.”
Focus on reducing net losses and improving operating income through expense management and revenue growth.
Stated as a priority in 2 of last 2 quarters. Net income improved significantly in 2026-Q1 to $846,100 from a loss of $5.9 million in 2025-Q1, driven by reduced R&D expenses. However, net loss remained at $4.47 million in 2026-Q2, slightly better than $4.59 million in 2025-Q2, with increased R&D expenses. The trajectory shows partial delivery with mixed progress on reducing losses.
“Net loss was $4,469,095 for 2026-Q2 compared to $4,585,922 in 2025-Q2; R&D expenses increased by 37.6%.”
“Net income was $846,100 for 2026-Q1 compared to net loss of $5,896,839 in 2025-Q1; R&D expenses decreased by 55.9%.”
Form and leverage partnerships to commercialize fertility and birth control products in new markets internationally.
Stated as a priority in 2 of last 2 quarters. Management formed partnerships to expand market access in Israel and Switzerland. While these partnerships demonstrate strategic progress, no specific revenue or volume milestones were disclosed, indicating ongoing execution with limited quantifiable delivery so far.
“Established strategic partnership with AMI Technologies to commercialize fertility portfolio in Israel.”
“Entered strategic distribution partnership with OR Consulting to support commercial launch in Switzerland.”
Advance FemBloc through clinical trials and regulatory processes to achieve U.S. FDA approval.
Stated as a priority in 2 of last 2 quarters. Management has initiated and continued enrollment in the FemBloc pivotal trial aiming for U.S. FDA approval. No regulatory approval has yet been announced, indicating ongoing progress but no milestone delivery yet.
“Advancement of FemBloc clinical and regulatory program toward U.S. approval.”
“Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc for U.S. approval.”
Over the trailing year it converted 1.26x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
22 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.